Other
Erythema
33
Pipeline Programs↗
5
Active Trials↗
21
Companies Involved↗
Erythema is a moderately active landscape with 33 programs across 21 companies. The most active players are Merck & Co., Bayer, Vicept Therapeutics, Inc.. 10 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 14
Phase 26
Analysis
Trial Status
56
clinical trials
Completed42 · 75%
Unknown status4 · 7%
Recruiting3 · 5%
Terminated3 · 5%
Withdrawn2 · 4%
Active, not recruiting1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
56 trials
The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·N/A·NCT07343635·186 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)